This week in industry we’re taking a look at the discontinuation of umibecestat and Acthar® Gel for Alzheimer’s and ALS, respectively, as well as the drug discovery shift from the amyloid approach in the Alzheimer’s field.
New studies presented at AAIC 2019 reveal that sex-specific differences could play a role in the risk, progression and resilience of Alzheimer’s disease.
Studies presented at AAIC 2019 have revealed the significant advances being made in the global search for blood-based biomarkers for dementia.
In this review article, published in the journal Immunotherapy, the authors explore immunotherapy for neuroblastoma from therapeutic backbone to the latest discoveries.
Take a look behind the scenes of a recent paper in Biomarkers in Medicine as we ask the author about oligomeric α-synuclein in basal tears of Parkinson’s patients.
In this Editorial published in Immunotherapy, researchers explore the use of antibodies directed against amyloid-β oligomers for Alzheimer’s disease.